- Global Pharma News & Resources

Strateos Closes $56 Million Series B Financing to Accelerate the Roll-Out of its SmartLab of the Future Platform

New financing led by DCVC and Lux Capital, will expand the next generation of smart lab solutions with direct access to automation to accelerate discovery in the life sciences

MENLO PARK, Calif.--(BUSINESS WIRE)--#AI--Strateos, Inc., a pioneer in the development of remote access laboratories and lab control software for life science research, today announced the closing of its $56.1 million Series B financing led by DCVC and Lux Capital with participation from new investors including Eli Lilly and Company, Ally Bridge Group, Black Diamond Ventures, Mack & Co., LLC, and Castor Ventures. With this financing, Strateos will continue to drive innovations on its SmartLab Platform™, which integrates data generation and AI-enablement with its unique and flexible automation to accelerate pharmaceutical and synthetic biology R&D.

“Life science research needs faster, more reliable and lower cost data to fully leverage artificial intelligence-powered analysis tools,” said Mark Fischer-Colbrie, CEO at Strateos. “Our unique fleet of lab automation modules, which can be accessed from anywhere in the world, speed the design-make-test-analyze cycle and generate clean, AI-enabled data. Strateos is pleased to have the backing of these world-class investors who bring deep expertise in building and scaling innovative platforms at the intersection of the life sciences and information technology. With their support, Strateos is re-imagining the world of life science research and ushering in a new era of decentralized discovery.”

Strateos leverages the resources of the company’s two SmartLab Studios in Menlo Park and San Diego, California, which together represent more than 14,000 square feet of laboratory space and 200-plus state-of-the-art research instruments tailored to the application needs of small-molecule and biologics drug discovery, cell and gene therapies and synthetic biology. These remote-controlled, secure labs are accessed through sophisticated command-and-control tools that enable scientists to design, manage, and collaborate on scientific workflows that deliver high-quality data that can be readily analyzed and shared. Strateos’ life sciences customers are also leveraging the Command & Control software to improve their internal operations and laboratory facilities locally, and worldwide.

“The Strateos team has truly built the lab of the future and is liberating scientists from the limitations of their location or lack of access to automation by creating a direct route to smart labs,” said Lux Capital Co-Founder and Managing Partner Josh Wolfe. “Data is the most important resource in scientific discovery and rethinking labs as quality-driven data centers will help the life sciences industry take advantage of this valuable asset. We are excited to partner with the forward-looking team at Strateos and join them in their mission to help change the pace of life science discovery for the benefit of all.”

About Strateos

Strateos is a pioneer in the development of remote access laboratories and lab control software for life science discovery. Our mission is to create new knowledge driven by data, computation, automation, and high-throughput robotics with the goal of fundamentally advancing the life sciences. The Strateos SmartLab Platform™ helps scientists more efficiently and reproducibly design, run, and analyze experiments to achieve new and faster scientific discoveries. For more information, please visit


Colin Sanford

Editor Details

  • Company:
    • Businesswire
Last Updated: 08-Jun-2021